2025-04-01
Eli Lilly is coming after makers of copycat versions of Zepbound
Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.
[...]Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
2025-03-27
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s
Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s d [...]
2025-03-14
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]
2025-03-10
Eli Lilly CEO David Rick’s’ pay rose to nearly $30 million in 2024
Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.Read more.. [...]
2025-03-28
Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approval
The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain swelling and bleeding. It’s a major setback for the company as it co [...]
2025-01-03
CES 2025: The new tech we're expecting to see from Samsung, NVIDIA, LG and more in Las Vegas
Time to get into the habit of writing "2025" instead of 2024, and the year may have just begun, but the Engadget team is already working hard for CES 2025. This weekend, many from the Engadg [...]
2025-03-17
The cost of GLP-1s needs to come way down for benefits to be worth it, study says
While weight-loss drugs like Zepbound (LLY) and Wegovy (NVO) offer significant health benefits, their high costs make them economically inefficient under current U.S. healthcare standards, according t [...]
